← All trials
NCT03835533
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2019
- Primary completion
- Mar 31, 2022
- Completion date
- Mar 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The Parker InstituteLead sponsor
- Cancer Research InstituteCollaborator
- Celldex TherapeuticsCollaborator
- Inovio PharmaceuticalsCollaborator
- Oncovir, Inc.Collaborator
- The Parker InstituteStudy director
- Bristol-Myers SquibbCollaborator
- The Parker InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.